Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB ; day:11 ; month:5 ; year:2024 ; pages:1-13
European journal of nuclear medicine and molecular imaging ; (11.5.2024), 1-13
- Creator
-
Cao, Zhipeng
Wichmann, Christian Werner
Burvenich, Ingrid Julienne Georgette
Osellame, Laura Danielle
Guo, Nancy
Rigopoulos, Angela
O’Keefe, Graeme Joseph
Scott, Fiona Elizabeth
Lorensuhewa, Nirmal
Lynch, Kevin Patrick
Scott, Andrew Mark
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-024-06742-6
- URN
-
urn:nbn:de:101:1-2407221026201.527125907471
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cao, Zhipeng
- Wichmann, Christian Werner
- Burvenich, Ingrid Julienne Georgette
- Osellame, Laura Danielle
- Guo, Nancy
- Rigopoulos, Angela
- O’Keefe, Graeme Joseph
- Scott, Fiona Elizabeth
- Lorensuhewa, Nirmal
- Lynch, Kevin Patrick
- Scott, Andrew Mark
- SpringerLink (Online service)
Other Objects (12)
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG
ATG- Drängrabenfräse
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG
ATG- Drängrabenfräse
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG